Hook & thesis
BRIUMVI is no longer a speculative pipeline play — it is a revenue growth story. TG Therapeutics' multiple sclerosis therapy continues to ramp: management raised full-year revenue guidance and reported consecutive quarters of strong top-line growth. With the stock trading at $55.40 and constructive technicals, I'm upgrading the rating to Buy and proposing a tactical long to capture what I see as meaningful upside over the next several weeks to months.
The case is straightforward: paid prescriptions and market penetration for BRIUMVI are expanding, the company is commercializing additional dosing formats and indication work is underway, and headline marketing/collaboration efforts have increased awareness among patients and physicians. Those operational levers — combined with bullish technical momentum and meaningful short interest that can amplify moves — make this an attractive risk/reward entry at current levels.
What the company does and why investors should care
TG Therapeutics, Inc. develops and commercializes treatments for B-cell malignancies and autoimmune diseases. The commercial center of gravity today is BRIUMVI, the company’s multiple sclerosis therapy. The business case for investors is simple: if BRIUMVI continues to grow at high double-digit rates and management executes on dosing-format improvements and label expansion, revenue and earnings should continue to outpace what the market previously expected.
Fundamentals and numbers that matter
Recent results show the real-world translation from regulatory wins to commercial performance. In Q1 2025 TG reported $119.7 million in U.S. net sales of BRIUMVI and raised full-year guidance. Q2 2025 revenue was described as up 91% year-over-year and management increased full-year revenue guidance to $585 million (announcement on 08/04/2025). That cadence — consecutive beats and a raised guide — is the foundation of today's bullish stance.
Key headline metrics:
| Metric | Value |
|---|---|
| Current price | $55.40 |
| Market cap | $8.48B |
| Shares outstanding | 153,069,041 |
| EPS (most recent) | $2.88 |
| Price / Earnings | ~19 - 20x |
| Price / Sales | ~10.6x (trailing) |
| EV / EBITDA | ~64x |
| Free cash flow (most recent) | $17.39M |
| Debt / Equity | 1.23x |
| Return on Equity | ~73% |
Two things jump out from these figures. First, the company is profitable on a GAAP/earnings basis (EPS ≈ $2.88) and the market is valuing that profitability at roughly 19-20x earnings — not egregious for a high-growth pharma commercializing a successful product. Second, other valuation metrics tell a different story: trailing P/S of ~10.6x and an EV/EBITDA north of 60x show the market is pricing in continued high growth and years of earnings expansion. Free cash flow is still relatively modest at $17.39M, so the company’s valuations embed expectations for continued margin expansion and significant top-line growth.
Technicals and market structure
The technical picture supports a bullish trade. The share price sits above the 9-, 21-, and 50-day EMAs (EMA-9 ≈ $52.67; EMA-21 ≈ $51.90; EMA-50 ≈ $50.58) and the 50-day simple moving average is $53.12. Momentum indicators are constructive (RSI ~60.8, MACD in bullish territory). Average daily volume over recent weeks is roughly 2.29 million shares, giving decent liquidity for entering and exiting positions. Short interest is material — about 30.1 million shares with days-to-cover in the low double-digits — which can intensify moves to the upside if earnings and guidance continue to outperform.
Valuation framing
At a market cap of approximately $8.48 billion and the company’s raised revenue guidance of $585 million for the year, the market is effectively pricing TG at ~14.5x 2025 guidance (8.48B / 585M). That’s a premium multiple for a commercial-stage drug, but not unreasonable given the company’s strong margins, high ROE and potential for label and formulation extensions (subcutaneous BRIUMVI, progressive MS programs). Comparing to peers isn’t straightforward here because TG sits at the intersection of profitable commercial pharma and growth-stage biotech expansion, but the core takeaway is this: the valuation reflects growth already in place and more growth priced in. The trade is a bet that management continues to deliver the operational milestones supporting that premium.
Catalysts (what could drive the stock higher)
- Continued quarterly beats and another guide raise when TG reports results that confirm BRIUMVI momentum.
- Progress or positive readouts on subcutaneous BRIUMVI and any signals for progressive MS, which would broaden the addressable market.
- Marketing and awareness initiatives — recent collaboration with Christina Applegate (02/08/2026) increases patient awareness and could improve prescription starts and adherence.
- Institutional re-rating as the company transitions from 'commercial validation' to 'scale' with sustained revenue and margin expansion.
Trade plan (actionable)
Recommendation: Upgrade to Buy. Enter a long at $55.40.
Trade specifics:
- Entry: $55.40
- Stop loss: $47.00 — tight enough to protect capital if BRIUMVI growth stalls, wide enough to avoid noise around near-term volatility.
- Primary target: $70.00 within a mid term (45 trading days) horizon.
Rationale for horizon: mid term (45 trading days) is long enough for one quarterly update or multiple small commercial/catalyst announcements to move real prescribing behavior, and short enough to maintain tactical discipline. If the company posts another quarter of sequential BRIUMVI growth or headlines positive progress on dosing/formulation, $70 is a realistic, reachable level given the current technical backdrop and short-interest dynamics. If momentum continues beyond that point, consider holding toward a longer-term target or scaling out.
Stretch idea
If TG reports another guide-raise and meaningful adoption signals, the stock could test higher targets in the $80s over a longer horizon (180 trading days). That would require continued execution and visible margin expansion to justify stretching the EV/EBITDA multiple down from the current level.
Risks and counterarguments
- Execution risk: Commercial execution can falter. Prescription starts, payer coverage or adherence could disappoint and slow revenue growth relative to expectations.
- Valuation vulnerability: The stock trades at a premium on several metrics (P/S, EV/EBITDA). Any evidence that growth will be slower or margins will compress could trigger a sharp multiple contraction.
- Debt and cash dynamics: Debt-to-equity is ~1.23x and free cash flow is still modest ($17.39M). A material slowdown in revenue could pressure liquidity or force financing/dilution.
- Regulatory / competitive risk: New entrants or label setbacks in MS space could reduce BRIUMVI’s pricing power or share. Reimbursement dynamics always pose a structural risk.
- Litigation / governance noise: Recent outreach by a law firm seeking plaintiffs (07/17/2026) introduces headline risk. Even if meritless, legal processes can be distracting and create volatility.
Counterargument to the bullish thesis
One plausible counterargument is that the market has already priced in most of BRIUMVI’s near-term upside. The company’s premium trailing multiples and high implied forward P/S (~14.5x on 2025 guidance) mean that even a single quarter of slower-than-expected uptake or a conservative guide could prompt an outsized downside move. In that scenario, the stock could give back a significant portion of its gains as investors reprice growth expectations. That is why the stop at $47 is essential — it limits downside if the market re-evaluates growth assumptions quickly.
What would change my view
I would raise conviction materially if TG reports another quarter of robust BRIUMVI sales and increases full-year guidance again, or if subcutaneous BRIUMVI or progressive MS data show clear differentiation — those outcomes materially improve the revenue runway and justify the current premium. Conversely, my outlook would weaken if (1) sequential sales growth stalls, (2) net new prescription data show weakening starts or payer headwinds emerge, (3) cash flow remains constrained and the company announces dilutive financing, or (4) a regulatory or litigation event meaningfully increases uncertainty.
Bottom line
TG Therapeutics is a growth story that has already begun producing real revenue. That transition from promise to performance supports an upgrade to Buy at $55.40 with a $70 target over a mid-term (45 trading days) horizon and a protective $47 stop. Execution is the key: continued sales growth, margin expansion and positive clinical/commercial catalysts should keep the momentum intact; any meaningful slowdown would force a reassessment.
Note: trade sizing should reflect your portfolio risk tolerance and the fact that biotech and specialty pharma stocks can exhibit above-average volatility around commercial and clinical milestones.